Randomized trial · people

Exenatide, alone or with dapagliflozin, improved blood sugar in PCOS

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, weekly exenatide paired with dapagliflozin gave the broadest metabolic gains in women with PCOS and obesity, and the blood sugar gains held up even when another drug matched its weight loss.

Kind
Randomized trial
Studied in
People
Number studied
119
Published
2021
Journal
J Clin Endocrinol Metab

What they tested

The team compared five drug options to see how each changed metabolism, body makeup and sex hormones in women with obesity and polycystic ovary syndrome (PCOS).

How the study was done

A single-blinded randomized trial in 119 women without diabetes, aged 18-45, with a BMI above 30 and below 45 and PCOS. For 24 weeks, each woman took one of five options: once-weekly exenatide (the 2 mg weekly arm), dapagliflozin 10 mg daily, both together, dapagliflozin with extended-release metformin, or phentermine/topiramate.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Exenatide plus dapagliflozin and phentermine/topiramate led to the most loss of weight, waist size and total body fat measured by DXA, a body scan. Phentermine/topiramate matched the combination on BMI and waist loss. Even so, only exenatide plus dapagliflozin and exenatide alone significantly improved mean blood glucose and measures of insulin sensitivity and insulin secretion from oral glucose tolerance tests. All five options lowered fasting glucose, testosterone, free androgen index (a measure of active male-type hormones) and blood pressure.

What it doesn’t show

The trial ran 24 weeks and had no placebo arm, so every group got an active drug. It included only women without diabetes who had obesity and PCOS, so it doesn't show how these drugs work in other groups.

The paper

Elkind-Hirsch et al. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021.

The compound

More studies on Exenatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo